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Abstract
There is emerging evidence that resident microbiota communities, that is, the micro-
biota, play a key role in cancer outcomes and anticancer responses. Although this has
been relatively well studied in colorectal cancer and melanoma, other cancers, such
as breast cancer (BrCa), have been largely overlooked to date. Importantly, many of
the environmental factors associated with BrCa incidence and progression are also
known to impact the microbiota, for example, diet and antibiotics. Here, we explore
BrCa risk factors from large epidemiology studies and microbiota associations, and
more recent studies that have directly profiled BrCa patients' gut microbiotas. We
also discuss how in vivo studies have begun to unravel the immune mechanisms
whereby the microbiota may influence BrCa responses, and finally we examine how
diet and specific nutrients are also linked to BrCa outcomes. We also consider future
research avenues and important considerations with respect to study design and
implementation, and we highlight some of the important unresolved questions, which
currently limit our overall understanding of the mechanisms underpinning
microbiota-BrCa responses.
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1 | INTRODUCTION
Annually, breast cancer (BrCa) is predicted to affect over 2 million
new patients, with more than 600 000 BrCa-related deaths world-
wide, second only to lung cancer in incidence and mortality.1 The
financial implications of the disease on patients and health services
are equally staggering with average treatment costs ranging from
£22 000 to £115 000 for a single patient depending on disease
stage.2 Moreover, while patients diagnosed in early stages usually
have good prognostic outcomes, those diagnosed in late stages of the
disease have very poor 5-year survival rates, less than 30%.2 Thus,
understanding the factors that drive BrCa development and progres-
sion is important not only for patient outcomes but also for alleviating
financial burdens on healthcare systems.
BrCa is an extremely heterogeneous disease and thus tradi-
tional therapeutic approaches are dependent on disease classifica-
tion. There are six molecular subtypes of the disease, luminal
A, luminal B (HER2+ of HER2−), HER2-enriched, normal-like
and basal-like or triple-negative breast cancer (TNBC) (Table 1),
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which are classified according to the expression of several
proteins.3-6
Crucially, expression of these proteins determines which thera-
pies clinicians employ to treat the disease such as neoadjuvant hor-
mone therapies, chemotherapies and/or radiotherapies.7,8 Successful
treatment outcomes rely on efficient activation of anticancer
responses, therefore delineating factors that beneficially or negatively
impact associated immune responses are key. One such emerging
modulator of BrCa aetiology is the gut microbiota, which may repre-
sent a viable therapeutic target for altering the course of the disease.
2 | BrCa RISK FACTORS: IS THE
MICROBIOTA A MISSING LINK?
Alongside known genetic factors, all cancers are considered to have
an “environmental” element associated with increased risk and dis-
ease progression. These associations are often uncovered in large
human epidemiological studies that correlate lifestyle factors (eg,
smoking, drug exposure and diet) with cancer onset and clinical out-
comes.9-11 As many of these factors are also known to alter the gut
microbiota, population-based association studies at least intimate
that the gut microbiota dictates cancer outcomes.9,12,13 A stable and
diverse microbial ecosystem (in adults) is considered optimal for
health, although the exact taxa that confer beneficial effects is an
ever changing conundrum, and is dependent on age, diet, medica-
tions, host genetics and numerous other external factors. In many
cases, a reduction in alpha and beta diversity is associated with
increased disease risk for many conditions, but correlations with
specific microbial taxa may change between patient cohorts. In
terms of “beneficial” bacterial members, those best studied include
some of the following: Bifidobacterium, Lactobacillus, Akkermanisa,
Ruminococcus, Bacteroides and Faecalibacterium; however, species
and strain-level differences are key considerations. More recent
studies indicate that overall function of the total microbial commu-
nity may allow more “healthy” signatures to be found, as recently
described for colorectal cancer (CRC) and choline degradation.14 For
reviews on this subject, see References 15 and 16. The gut-tumour
connection includes sites known to have direct cross talk between
the host and the gut microbiota (eg, CRC), but also in sites distal to
the gut (eg, the skin, liver and breast). It is likely that, what applies in
one cancer setting is by no means universal, and BrCa, by its
extreme heterogeneity and relative low incidence of genetic predis-
position, is particularly unique. Consequently, there are many large
studies focused on understanding how different environmental fac-
tors influence BrCa, and each of these factors influence (and are
influenced by) the microbiota. These include the following:
1. Diet: In the 1990s, several groups investigated the association
between diet and BrCa risk. For example, a low-fat diet elicited a
lower risk of relapse after tumour resection.15 Recent meta-
analyses of cohort studies continue to correlate dietary patterns
with BrCa risk.16 This topic is covered in more detail in Section 3
of this review.
2. Obesity: Complementary to a low-fat diet, obesity is associated
with increased risk of developing postmenopausal BrCa with a
worse clinical outcome. Meta-analysis of nine studies showed
increased BrCa risk with increased body mass index (BMI).17 Asso-
ciations between obesity and postmenopausal BrCa may be due to
adipose tissue catalysing the formation of oestrogen after meno-
pause, thereby increasing circulating oestrogen levels17,18; see
Point (4).
3. Alcohol consumption: Excessive alcohol intake is also recognised as
a risk factor for BrCa.19 Although the specific molecular mecha-
nisms driving this correlation remain unknown, ethanol may
(a) induce molecular damage in mammary cells; (b) inhibit
oestrogen-metabolising enzymes in the liver; (c) increase aroma-
tase activity in the liver, which has been reported to facilitate the
conversion of testosterone to oestrogen20; see Point (4).
4. Changes in circulating hormonal levels: Alongside uterine, ovarian
and prostate cancers, some forms of BrCa are oestrogen driven.
Both a late menarche and an early menopause decrease the risk of
developing BrCa.11 For a recent review on this subject, see Refer-
ence 21.
5. Antibiotic exposure: Use of antibiotics is becoming increasingly con-
troversial, with unexpected adverse effects being reported in several
disease contexts.22-24 In 2004, Velicer et al concluded that cumula-
tive days of antibiotic exposure were associated with increased risk
of BrCa.25 A follow-up study also showed that antibiotic use may be
associated with less favourable tumour features.26
TABLE 1 BrCa subtypes defined by receptor status and proliferative potential as based on Ki67 expression
BrCa Subtype
Receptor status
Ki67 expressionER PR HER2 Clinical prognosis
Luminal A + + − Low Good
Normal-like +/− +/− − Low Intermediate
Luminal B (HER2−) + +/− − Any Intermediate
Luminal B (HER2+) + +/− + High Intermediate
HER2-enriched − − + Any Poor
Basal-like/TNBC − − − Separate basal markers used,
for example, claudin
Poor
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One commonality between each of these risk factors is that they
significantly alter the profile of the gut microbiota (see Table 2),
suggesting a strong link between microbiota make-up and BrCa devel-
opment. This suggests that a perturbed microbiota and therefore
altered microbial-associated functions may impact BrCa risk. Gener-
ally, in terms of microbiome changes and duration of these alterations
in response to different factors, certain “resilient” individuals may
have a rapid but only transient change in microbiome profiles, while
others may have large-scale changes that persist over many years
(often compounded during the early life window), after introduction
and removal of, for example, antibiotics and dietary interventions.37
However, this is dependent on the baseline microbiota of individuals,
and in many cases we do not understand the impact of these factors
on specific microbial communities, species and strains, which may play
a key and oversized beneficial role. Further studies are needed in this
area, including within BrCa patient cohorts.
3 | GROWING EVIDENCE LINKING
THE GUT MICROBIOTA AND BrCa
Changes in the abundance (ie, levels) of particular microbes have been
associated with several cancers. A well-known example is Helicobacter
pylori, which initiates gastric inflammation and the formation of pre-
cancerous lesions.38 Likewise, increases in Fusobacterium spp. are
associated with increased risk of developing CRC.39
Functional pathways linking specific microbiota members and BrCa
have yet to be shown, but gut microbiota profiling of BrCa patients has
indicated that there may be microbial signatures associated with dis-
ease stage and outcomes. Microbiota profiling methods and analysis
tools are varied and there are important points to be considered when
designing or interpreting these types of studies. Microbiota profiling of
the Twins UK cohort, which comprises a large number of older women,
indicated that BrCa incidence correlated with “disrupted” or a non-
healthy microbiota signature,40 suggesting that the gut microbiota may
represent a useful biomarker and/or treatment focus for BrCa patients.
Studies looking at postmenopausal BrCa patients have shown that
these women had an enrichment of 38 species compared to postmeno-
pausal controls, these included species positively (albeit) weakly associ-
ated with oestrogen metabolism (Shewanella putrefaciens and Erwinia
amylovora), short-chain fatty acid butyrate producing species (Roseburia
inulinivorans) and a species that was negatively but weakly associated
with tumour-infiltrating immune cells (Actinomyces sp. HPA0247).41 In a
different study by Goedert et al, an altered microbiota signature in the
same subtype of BrCa patients, that is, postmenopausal BrCa was
observed; lower alpha diversity and increased relative abundance in
TABLE 2 BrCa risk factor and microbiota associations
Factor Influence on the gut microbiota
Diet (covered in more
detail in Section 3)
• Members of the microbiota can digest otherwise indigestible components of our diet (eg, dietary fibre)
• Dietary fibre constituents can (a) boost nutritional intake, (b) act as a substrate for other microbiota members to
colonise and (c) act as a metabolite27
 Short-chain fatty acids (SCFA), a constituent of metabolised dietary fibre, can module host immune responses
 Bioactive compounds, a constituent of metabolised polyphenols, encourage growth of beneficial bacteria for
example, Bifidobacterium and Lactobacillus and production of SCFA28,29
Obesity • Gut microbiota profiles differ among obese and lean patients and between those with metabolic syndrome30
• In mice, studies showed that an obese microbiota profile had a greater nutritional intake capacity31
 Members of an obese microbiota profile encoded enzymes that could more efficiently degrade
polysaccharides
Alcohol • Perturbations of the gut microbiota profile was observed in alcoholics vs nonalcoholics32
 This resulted in lower abundance of Bacteroidetes and higher abundance of Proteobacteria
 Alcoholics also had higher levels of serum endotoxin
• Alcoholics tended to have greater gut permeability, which could lead to a local inflammatory state and disease,
for example, alcohol-related liver disease33
• It can be hypothesised that changes in microbiota members due to alcoholism alter the metabolites available by
the host to use for other physiological processes including gut barrier function
Hormones • In 1998, a group observed that germ-free mice, which do not have a gut microbiota, regained normal oestrous
levels upon accidental bacterial contamination
 This suggested a link between gut bacteria and reproductive capacity34
• Microbiota members possess ß-glucoronidase, which can deconjugate already metabolised oestrogen
 Thereby increasing levels of systemic oestrogen, increasing the risk of ER+ breast cancer35
• A population-based study demonstrated an association between oestrogen metabolism and phylogenetic
diversity of the gut microbiota, suggesting a link between the gut bacteria and circulating reproductive
hormones34
Antibiotics • Antibiotics severely impact the gut microbiota, most notably they reduce microbial diversity
 After depletion due to antibiotics it became easier for pathogenic bacteria, for example, Salmonella to colonise
due to lack of competitive exclusion36
 The change in microbiota members consequently influenced the availability of metabolites used by the host,
which could influence, for example, host immune responses36
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classes Clostridiaceae and Ruminococacceae and in Faecalibacterium,
and a relative decrease in abundance of Dorea and Lachnospiraceae.42 In
short, these studies suggest that postmenopausal BrCa patients do
have an altered microbiota signature, which was reported in the Twin
UK cohort study.40 Guan et al assessed microbiota profiles of HER2
metastatic BrCa patients undergoing metronomic Capecitabine. They
observed different microbiota profiles and reduced diversity in
Capecitabine vs conventional patients. Further microbiota probing
suggested that Blautia obeum was significantly associated with
progression-free survival in Capecitabine, while Slackia was negatively
associated with progression-free survival.43 Wu et al recruited 37 BrCa
patients and assessed the microbiota profile based on their tumour
characteristics. The group observed that patients who were positive for
HER2 had a significantly lower alpha diversity. In addition, they found
that patients with a higher tumour grade were associated with a higher
abundance of Clostridium and Veillonella, and a lower abundance of
Erysipelotrichaceae.44 Both Veillonella and Erysipelotrichaeceae have
previously been reported to correlate with inflammatory conditions.45
In the same study, the group assessed microbiota changes to
recognised BrCa risk factors, for example, BMI and menarche. They
observed that an early age of menarche was associated with a lower
microbiota diversity—which may suggest a link with circulating
oestrogen.44 Furthermore, larger studies (considering other microbiome
confounders) are required to explore patterns/relationships, which may
be at the functional level rather than through shared taxa—as recently
indicated in CRC (and choline degradation).14
Although longitudinal human studies facilitate important insights
into the complex relationship between the gut microbiota and BrCa,
there are numerous ethical and logistical issues that preclude their use
for understanding detailed mechanisms. Thus, in vivo models are cru-
cial to better define the underlying mechanisms driving specific obser-
vations under robust controlled conditions.
4 | ANIMAL STUDIES OF THE LINKS
BETWEEN THE GUT MICROBIOTA AND BrCa
To date, there is still a relatively limited body of research exploring the
role of the microbiota and different in vivo BrCa models, although inter-
est is growing, and lessons learned from other cancers may be applica-
ble in this underresearched area. Crucially, studies to date have
indicated that microbiota modulation of the immune system may repre-
sent a key cross-roads determining disease and treatment outcomes. A
distinct advantage of using preclinical models is the ability to explore
the impact of microbiota on different BrCa subtypes, which is key given
the heterogeneous nature of this cancer type (see Table 1).
4.1 | Evidence of microbiota involvement
in non-BrCa disease
Understanding mechanistic links between the gut microbiota and BrCa
is in its infancy. Thus, to better gauge the potential for the microbiota
to influence BrCa occurrence and progression, it is important to con-
sider the larger body of literature confirming such links in non-BrCa dis-
ease. Disruption of gut homeostasis and effects on local inflammatory
diseases have been well researched in animal models. Thus, it is unsur-
prising that CRCs were some of the first to be linked to changes in
microbial communities, for example, increased Fusobacterium nucleatum
abundance has been heavily associated with colorectal carcinogenesis
(as mentioned earlier). However, without the use of animal models, it is
difficult to conclude whether such changes are causative of disease or
simply a product of it. Recently, animal studies have been able to
explore these relationships in more detail, for example, Yu et al identi-
fied that subcutaneous xenograft tumours, derived from SW480 colon
adenocarcinoma cells, intratumorally injected with F. nucleatum were
resistant to oxaliplatin chemotherapy through an autophagy-dependent
pathway,46 suggesting a protumorigenic influence of the bacteria.
Microbes have also been observed to play antitumorigenic roles,
which in many cases appears to be via education of the host immune
system. One of the seminal studies in the microbiome cancer field
identified an association between Bifidobacterium abundance and
reduced melanoma tumorigenesis in a subcutaneous allograft B16.
F10.SIY model in C57/BL6 mice.47 The same study observed that oral
administration of a cocktail of Bifidobacterium species combined with
an immune checkpoint inhibitor immunotherapy targeting the PD1—
PD-L1 signalling pathway using an anti-PD-1 monoclonal antibody
promoted activation of CD8+ cytotoxic T cells and significantly
reduced tumour outgrowth.47 Tanoue et al presented similar findings
when administering mice with a consortium of 11 bacterial strains iso-
lated from healthy human faeces, including those of the genus
Bifidobacterium and Lactobacillus, describing improved CD8 T-cell acti-
vation and improved efficacy of immune checkpoint inhibitor thera-
pies.48 Furthermore, Gopalakrishnan et al went on to confirm a similar
outcome in human patients, whereby those with an increased micro-
bial diversity responded more favourably to anti-PD-1 immunother-
apies than patients with lower diversity.49
4.2 | BrCa literature
With the awareness that non-BrCa disease is influenced by changes
in the microbiota, we can now ask if similar affects are observed in
BrCa models. Unlike in melanoma, the lower expression of immune-
modulating proteins, such as PD-1 and CTLA-4, in BrCa means it is
less amenable to checkpoint inhibition therapies.50,51 However, the
immune system still plays a key role in both pro- and anticancer
responses at different stages of BrCa progression. In one of the earlier
microbiota—BrCa studies, Rao et al observed that Helicobacter
hepaticus infection in C57/BL6 ApcMin/+ mice (spontaneous CRC
model) resulted in the formation of tumours in the breast as well as in
the colon.52 In a similar model deficient in the Rag2 gene, thus lacking
mature lymphocytes, tumours were more frequent with increased
infiltration of F4/80+ myeloid cells, suggesting a protective role of
lymphocytes in reducing innate immune inflammation associated with
tumourigenesis. Indeed, dosage of Rag2-deficient animals with
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CD4+CD45lowCD25+ T-regulatory cells from wild-type animals signifi-
cantly reduced breast tumourigenesis, including in H hepaticus
infected animals.52 This supports the consensus that microbes have
an integral role in priming the immune system, particularly the adap-
tive components, to act against cancers distal to the GI tract.
More recent studies have focused on the impact of loss of known
mutualistic bacterial genera and species, and the impact of microbial
metabolites on BrCa progression (also discussed later). One of the most
influential factors contributing to disruption of the gut microbiota is anti-
biotic use, which has been linked to increased risk of several cancers
including BrCa.53,54 In a comprehensive study, Buchta Rosean et al
administered C57/BL6 mice with a robust antibiotic cocktail, comprising
vancomycin, neomycin, metronidazole, gentamycin and ampicillin, for
2 weeks to ablate the gut microbiota.24 Following a recolonisation period
of 4 days, animals were orthotopically induced with either a poorly meta-
static, hormone receptor positive model or a more aggressive PyMT-
derived model. A pre-perturbed microbiota significantly increased metas-
tasis to the lungs in both models, without influencing primary tumour
growth kinetics.24 Subsequent analysis of immune cell infiltration and
cytokine analysis of mammary tissue prior to tumour induction identified
increased abundance of myeloid cells and elevated myeloid recruitment
components including CXCL10 and CCL2, suggesting that metastatic
potential was promoted through antibiotic-induced inflammatory path-
ways independent of tumour status. McKee et al used a similar antibiotic
cocktail (swapping gentamycin for amphotericin), but continued treat-
ment throughout the experimental period.55 In contrast to Buchta
Rosean et al, they did observe a significant increase in primary tumour
kinetics when using orthotopic syngeneic models for both luminal
(PyMT-BO1) and basal-like (EO771) BrCa. Downstream scRNA-seq rev-
ealed an increased stromal signature (PyMT-BO1 only) and histological
analysis revealed increased abundance of mast cells tumour stroma in
PyMT-BO1 and EO771 tumours from antibiotic-treated animals. Nota-
bly, inhibition of mast-cell activation confirmed this immune population
to be driving enhanced primary tumour growth after antibiotic-induced
microbiota disturbances. Importantly, the same study also demonstrated
that using a clinically relevant cephalosporin antibiotic promoted the
same increase in primary tumour growth and was associated with similar
increases in tumour mast cells.55
Based on the similarity of the orthotopic models used in these
two studies, it is likely that the differences in primary tumour growth
between them were due to the differences in treatment regimen.
Buchta-Rosean et al allowed for a bacterial recolonisation period of
4 days, which likely aided in slowing primary tumour growth, possi-
bly through an immunological re-priming.24 However, McKee et al
undertook an uninterrupted antibiotic treatment, which may have
prevented mutualistic bacteria from recolonising, leaving the primary
tumour to grow “unchecked”.55 Nonetheless, both studies suggest a
healthy microbiota positively regulates antitumour immune path-
ways. Thus, it is surprising that to date there does not appear to be
any mechanistic in vivo studies into whether the administration of
beneficial or “probiotic” genera such as Bifidobacterium or Lactoba-
cillus may influence BrCa progression or support therapeutic inter-
vention against it.
The metabolome of the microbiota is also known to play a key
role in host health, influencing an array of biological pathways includ-
ing cellular proliferation, metabolism and immunity. Although studies
focusing on microbial metabolites in BrCa models are very limited, a
previous study determined that cadaverine (produced during microbial
breakdown of animal tissue) supplementation reduced both primary
and metastatic burden in an orthotopic 4T1 triple-negative-like BrCa
model in BALB/c mice.56 As highlighted previously, short-chain fatty
acid (SCFAs, particularly butyrate) also have links to cancer and are
known to promote an invasive/aggressive phenotype in BrCa
in vitro.57 Crucially, these microbial metabolites are derived after fer-
mentation/metabolism of dietary components and therefore diet may
act as a key overriding factor that impacts the microbiota, their
metabolites and subsequent host interactions, leading to differential
BrCa outcomes.
5 | DIET, THE GUT MICROBIOTA
AND BrCa
As already mentioned earlier (and in Table 2), extensive epidemiologi-
cal studies have laid the groundwork for understanding that diet has a
major role on cancer risk and progression.58-60 One of the key roles
played by the microbiota is breakdown of complex dietary substrates
into their constituent bioactive compounds; therefore, there is grow-
ing interest in understanding functional outcomes and the underlying
mechanisms governing diet-microbe interactions with respect to
cancer.
5.1 | Diet and BrCa
Although the correlations between BrCa risk and dietary intake have
been intensively studied, the underlying associations or effector
mechanisms remain poorly understood. Historically, increased risk of
BrCa has been tied to high intake of red meat and animal fat,61,62 with
decreased risk being concurrently linked to fruit and vegetables con-
sumption.63 The overall field remains conflicted, as epidemiological
links between individual foods and BrCa appear difficult to rationalise
within the confines of even large-scale observational studies. This
point is emphasised by the 2017 third expert report on “diet, nutrition
and physical activity in BrCa” by the World Cancer Research Fund/
American Institute for Cancer Research, which stated that although
body fatness (as adjudged by BMI and waist-to-hip ratio) was a proba-
ble risk factor for BrCa in premenopausal and postmenopausal
women, there is only limited or suggestive evidence for contribution
of any single food group.64 It is possible that these findings are a
result of the requirement for a change in total dietary pattern to have
significant effect on the gut microbiota and disease risk, or because of
the difficulty in conducting longitudinal human studies which focus on
a single food group. More recently, research has moved toward
assessment of dietary patterns (rather than specific foodstuffs), which
indicate that “Western” diets (ie, those that are high in processed
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meat, sugar and fat) increase BrCa risk, while a more “healthy” diet (ie,
high fresh fruit, vegetables and fish) decreases BrCa risk.16 Impor-
tantly, and specific to BrCa, menopausal status and BrCa subtype (ie,
receptor status) are important confounders when assessing dietary
links. Western diet effects, for example, are only significant in post-
menopausal patients with hormone receptor-positive tumours, while
“healthy” diet effects are only significant in premenopausal women,
but across receptor-positive and receptor-negative tumours.16 Alco-
hol intake is also a significant risk factor, with high consumption linked
with disease recurrence and reduced survival.65 Another dietary pat-
tern linked to BrCa is the Mediterranean Diet, with recent studies
showing an inverse relationship, particularly in the context of triple-
negative disease.66,67
5.2 | Diet and the gut microbiota
There is a strong evolutionary relationship between the gut micro-
biota and diet. Certain members genomically encode enzymes such as
glycoside hydrolases, which allow poly- and/or oligosaccharide carbo-
hydrates to be metabolised.68 Some “generalist” microbes, such as
members of the Bacteroides phyla (eg, Bacteroides thetaiotaomicron),
degrade a wide array of carbohydrates, while other “specialist” gut
microbes (eg, Rosaburia intestinalis) degrade specific oligosaccha-
rides.69 Ingestion of dietary fibre elicits a dynamic response from com-
munities of these metabolising microbes through extensive primary
and secondary degradation. Here, primary degraders (eg, B. the-
taiotaomicron) convert polysaccharides into oligosaccharides and sec-
ondary metabolites (eg, SCFAs), which can then be utilised by
secondary degraders (eg, Eubacterium rectale) to further enhance
nutrient bioavailability (eg, breakdown to monosaccharides) and sup-
port community colonisation.70 This so-called “cross-feeding” is a
determinant of gut population dynamics, as increased metabolism
often affords selective advantages, which increase microbe abun-
dance and subsequent digestion efficiency.69
Previous work in CRC has indicated that microbial-derived SCFAs,
particularly butyrate, have anticancer effects (demonstrated in cancer
cell cultures71,72 and animal models73); however, clinical supplementa-
tion studies have proved difficult due to issues with bioavailability and
toxicity.74 Therefore, a more nuanced microbiota and defined diet
approach may represent a more realistic avenue to improve cancer out-
comes. This highlights the interlinking relationship between microbiota
composition and metabolite production, with both factors requiring
consideration if we are to realistically improve cancer outcomes.
More recently, it is now appreciated that specific components from
fruit and vegetables (eg, polyphenols) may also be processed and influ-
ence the gut microbiota by acting as prebiotics (defined as dietary sub-
strates, which can be utilised by host microorganisms to confer a health
benefit).75 Dietary polyphenols have well-documented effects on the
host, which has been reviewed elsewhere.28 Studies have shown that
increased polyphenol intake is associated with higher levels of benefi-
cial bacteria (such as Bifidobacterium and Lactobacillus) and SCFAs in
humans, while also decreasing levels of bacteria that have been
associated with disease, so-called pathobionts.29 Polyphenols are
known to undergo extensive metabolism via the gut microbiota during
conversion to bioavailable metabolites. The magnitude and complexity
of these interactions have made detailed studies difficult, but some
examples of known biotransformations include Flavonifractor plautii
conversion of catechin and epicatechin into valerolactones and valeric
acids, and soy isoflavones into equol and/or O-desmethylangolensin by
Slackia isoflavoniconvertens and Slackia equolifaciens. Biochemical groups
of microbiota-modulating polyphenols include flavanols (eg, catechin),76
resveratrol77 and anthocyanins,78 which are highly concentrated in
foodstuffs such as green tea, berries and red-wine. While human mech-
anistic studies involving polyphenols and disease are lacking, the afore-
mentioned polyphenols are able to rescue high-fat diet (HFD)-induced
microbiota perturbations and elevate murine type II diabetes symptoms
through increases in gut Akkermansia species.79-81 Given the emerging
importance of the gut microbiota in tumour progression and cancer
therapy, dietary manipulation of the system (via dietary fibre and poly-
phenols) is an important theme to be explored in humans and via mech-
anistic in vivo studies.
5.3 | Mechanistic links between diet and BrCa
The majority of in vivo mechanistic knowledge is confined to tumours
“local” to the digestive tract (such as gastric, colon and CRC, as dis-
cussed earlier). This is perhaps expected, given gastrointestinal tissues
come into direct contact with bioactive compounds resulting from
digestion. Studies probing the mechanistic impact of diet on BrCa are
limited, and most studies to date have explored how HFDs are linked to
primary and metastatic tumours. One particular study indicated that an
HFD promoted formation of pre-metastatic niches and lung metastases
in mice through activation of myeloid-derived suppressor cells
(MDSC),82 but this HFD-induced metastasis could be significantly ame-
liorated through treatment with a saponin called glycyrrhizic acid, a
plant-derived phytochemical. Glycyrrhizic acid significantly altered
microbiota composition in this context, and concurrently reduced
colonic lipopolysaccharide (LPS), NF-kB and macrophage activity—
which correlated with decreases in MDSC infiltration to pre-metastatic
niches. Interestingly, the effect of glycyrrhizic acid was ablated through
microbiota depletion with antibiotics, causing re-introduction of HFD
levels of colonic LPS and implicating the gut microbiota as the key
effector in this model system. Mechanistic links between diet and BrCa
metastasis have also been made elsewhere, as it has been shown the
calorie restriction during radiotherapy (for TNBC) causes decreased
metastatic burden in mice compared to animals on an ad libitum diet.83
This decrease is caused by downregulation of the oncogenic insulin-like
growth factor-1/Akt pathway—a known regulator of tumour
metastasis.84
As previously mentioned, dietary polyphenol intake has been
linked with improved BrCa outcomes. To date, many of the studies
examining the anticancer properties of polyphenols have been per-
formed in vitro, and have often also used unmetabolised purified com-
pounds, therefore reflecting a direct anti-tumour therapeutic
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approach.85-87 Contrastingly, studies exploring dietary polyphenol
intake and their downstream effects on BrCa, within the context of
“normal digestion”, are thin on the ground. Of the limited mouse stud-
ies completed so far, dietary delivery of quercetin was shown to be
effective in reducing tumour number and volume in the C3/SV40 Tag
model of BrCa.88 Elsewhere, oral delivery of grape polyphenols (res-
veratrol, catechins and quercetin) decreased primary tumour growth
and metastases in a mouse xenograft model via downregulation of
NFkB,89 and oral piceatannol administration decreased 4T1 breast
tumour metastasis through inhibited macrophage infiltration and
angiogenesis.90
Although it is clear that diet, and specific components like fibre
and polyphenols, may play an important role in BrCa, comprehensive
studies directly linking the gut microbiota, dietary components and
BrCa progression are required to fully understand how we can manip-
ulate the system.
6 | FUTURE PERSPECTIVES
The field of microbiome and cancer is rapidly expanding, yet studies
focused on BrCa are currently limited. There is now a strong body of
evidence indicating the gut microbiota and associated factors such as
diet and antibiotics may play a key role in BrCa risk and outcomes,
therefore detailed mechanistic studies in preclinical models that help
underpin next-stage translational projects are needed. However, there
are some important considerations specifically in relation to BrCa that
need to be evaluated.
One such consideration relates to the differential risks between
BrCa subtypes (see Table 1), including treatment-resistant (eg, TNBC)
tumours. To date this fundamental BrCa factor has been somewhat
ignored, therefore future microbiota profiling studies of BrCa should
consider clear stratification of patients by histological and molecular
subtypes, which may allow comparison between groups and associ-
ated pathological outcomes. Age will also need to be carefully consid-
ered in these groups as the microbiota diversity does decrease in
elderly populations.91 Previous studies have indicated that healthy
individuals living at home have a more “robust” microbiota compared
to those living in long-term residential care (which may be linked to
diet). There are also alterations in microbiome composition associated
with frailty indices and inflammatory status.92 This is obviously impor-
tant for BrCa as, the older a woman is, the more likely she is to get
BrCa; rates are highest in women over 70.10 Furthermore, to date,
nearly all BrCa microbiome studies have focused on high-income
country patient populations. As BrCa rates are increasing in low-to-
middle income countries, which also have differing patient population
characteristics (age and BrCa subtype),93 further studies should estab-
lish signatures in diverse BrCa patient cohorts as this is crucial for
next-stage clinical trials and optimal patient outcomes. An important
consideration for microbiome and BrCa studies also relates to stan-
dard clinical care pathways. Typically, BrCa patients will undergo one
or more of the following: surgery, chemotherapy and/or radiotherapy.
Several studies are currently ongoing (either still recruiting or still to
publish results) to determine the impact of chemotherapy and the gut
microbiota on BrCa patients, for example, NCT03702868,
NCT04138979 or NCT03222856; however, findings are yet to be
published. Conversely, there appears to be no studies that are solely
focused on the relationship between radiotherapy in BrCa patients
and its impact on the gut microbiota and clinical outcomes, although
there appears to be studies with a radiotherapy aspect
(in combination with other therapies, that is, immune-checkpoint) but
not as a primary outcome (NCT04435964). Interestingly, in vivo stud-
ies from the 1960s have suggested that radiotherapy on germ-free
mice was less effective94; however, further studies—mechanistic and
clinical—are required to understand the influence of these differing
factors on the gut microbiota and BrCa outcomes.
Although the limited studies to date have indicated an altered
microbiota signature in BrCa patients, further research into the strain-
level variation and functional capacity of the microbiota, including a
focus on nonbacterial members, that is, viruses, fungi and archaea,
and also impact of external factors is required. This may allow more
specific biomarker profiling in relation to BrCa risk in relation to the
many microbiota-modulating factors earlier in life may predispose to
onset of cancer, including BrCa. Thus, longer-term longitudinal in-
depth profiling studies are key to understanding the impact of lifestyle
factors and routine medications (eg, antibiotics) on the microbiota
prior to detection of primary breast tumours. Enhanced microbiota
profiling studies may also allow patient stratification for treatment tri-
als (identifying potentially nonresponsive patients) in tandem with cur-
rent or new therapies (as described earlier). Moreover, more robust
microbiome-profiling approaches and tools are expected to facilitate
development and interventions/treatment with microbiota therapies
such as probiotics and/or live biotherapeutic products. Probiotics are
products that contain live microorganisms, which when administered
in adequate amounts can confer health benefits to the host.95 Certain
types of these probiotic microbes have been shown to stimulate
immune responses and also shown in vitro to exert antitumorigenic
potential via immunoregulatory pathways.96 However, to date, there
has only been a very small number of clinical trials to evaluate probi-
otic supplementation in BrCa patients: NCT03760653 and
NCT03358511. Unfortunately, the former was prematurely termi-
nated, while the latter has recently completed with only 7 participants
enrolled. It is clear that larger-scale randomised placebo controlled tri-
als are needed, but ideally these should be based on evaluation of pro-
biotics or live biotherapeutic products in vitro and in vivo to pinpoint
potential multifactorial mechanisms underlying beneficial effects, and
thus optimal strain(s) combined to take forward into BrCa patients.
For a recent review on this topic, see Reference 96.
As diet is a significant confounder for all microbiota studies, and
the apparent close links between diet and BrCa, food diaries (using
new apps) may provide important insight into the patient's dietary
habits. However, current dietary patterns may not reflect previous
eating habits, which may have contributed to disease development or
susceptibility. Future observational or clinical trials should seek to
control, or capture associated meta-data, which will be crucial for
teasing out causative or associative factors with respect to BrCa risk.
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Moreover, studies focused on diet/metabolites may also need to con-
sider if dietary interventions should be personalised if they are to be
successfully utilised for future therapy. Indeed, recent studies have
highlighted the personalised response to individuals (and the micro-
biota) to the same diet,97 which highlights the limitations and chal-
lenges for next-stage studies of this kind.
It is clear that more comprehensive preclinical data are required
in the field, and that choice of in vivo models is key. Consideration of
the models used, their clinical relevance, microbiota modulatory fac-
tors (eg, diet and antibiotics) and the approaches used to integrate
microbial and host components must be carefully reviewed. Although
subcutaneous tumour studies demonstrate to some extent that
microbes can influence carcinogenesis, it is beneficial to test such
hypotheses in more physiologically relevant orthotopic or spontane-
ous models, which better underpin the physiological and biomolecular
mechanisms involved in such phenotypes. Indeed, spontaneous
in vivo BrCa models may allow further insights into microbiome and
microbiota-modulating factors and BrCa risk, while orthotopic models
may allow testing of acute immune mechanisms and testing of new
promising therapies. The greater translational impact of these models
should provide greater clarity for moving preclinical research to
human studies. Moreover, studies focusing on dietary or antibiotic
interventions in mouse models should include downstream analyses
of the gut microbiota, mucosal and systemic immunity, as well as
microbial and host metabolism, so to develop a multisystem picture of
the effects of microbiota manipulations on BrCa risk and progression.
An important caveat to any resulting findings, however, is that mice of
the same genetic background housed at different animal facilities will
likely have different microbiota profiles, which may influence experi-
mental cancer outcomes.98 Overall, more comprehensive preclinical
findings will better inform and facilitate design of translational human
studies looking at the impact of defined dietary components on the
gut microbiota and BrCa outcomes, as well as profiling responders vs
nonresponders to treatments in the context of diet.
7 | CONCLUSIONS
The microbiome is emerging as a central player in cancer risk and anti-
cancer responses, and recent studies also suggest this may be the case
for BrCa. However, as many intrinsic and extrinsic factors are known
to influence the microbiota, and indeed the cancer itself may also
impact community composition, robust experimental design from
sequencing the microbiota to capturing meta-data, and the choice of
in vivo models, is required. A combination of approaches is most likely
to narrow down important causative or associative factors, which may
allow interventions to reduce BrCa risk, and guide the development of
novel therapeutic approaches to alleviate symptoms or improve prog-
nosis in BrCa patients.
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